Montmorillonite
CAS 1318-93-0
Montmorillonite (CAS 1318-93-0) is a pharmaceutical compound with 0 bioactivity targets and 947 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Montmorillonite is linked to DTXSID6051225 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| MONTMORILLONITE | 1425919 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Montmorillonite used for in pharmaceutical contexts?
Montmorillonite (CAS 1318-93-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Montmorillonite?
Montmorillonite has 947 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal distension, Abdominal pain, Abdominal rigidity, Acute kidney injury, Acute pulmonary oedema. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Montmorillonite also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Calcium Montmorillonite with EU status "permitted".
What clinical phase is Montmorillonite in?
No phase 1-4 clinical development badge is rendered for Montmorillonite because the matched compound identifier rows do not contain a max-phase value.